Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-blockers in heart failure

J N Cohn1

  • 1Cardiovascular Division, University of Minnesota Medical School, Minneapolis 55455, USA.

European Heart Journal
|July 4, 1998
PubMed
Summary
This summary is machine-generated.

Beta-blocker therapy shows promise in managing heart failure by slowing left ventricular dilation. Further research into specific mechanisms could personalize treatment for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study.

Journal of human hypertension·2012
Same author

Rationale for angiotensin II receptor blocker therapy in chronic heart failure.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2007
Same author

Relationship between C-reactive protein and arterial stiffness in an asymptomatic population.

Journal of human hypertension·2005
Same author

Angiotensin receptor blockers and clinical trials in heart failure.

European heart journal·2003
Same author

Small and large artery elasticity indices in peripheral arterial occlusive disease (PAOD).

Vascular medicine (London, England)·2002
Same author

Nuggets, pearls, and vignettes of master heart failure clinicians. Part 2-the physical examination.

Congestive heart failure (Greenwich, Conn.)·2002
Same journal

The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

European heart journal·2026
Same journal

Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

European heart journal·2026
Same journal

Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis.

European heart journal·2026
Same journal

Myths and misconceptions about high-sensitivity C-reactive protein as a marker of residual inflammatory risk.

European heart journal·2026
Same journal

Vascular Ehlers-Danlos syndrome: should we treat asymptomatic patients?

European heart journal·2026
Same journal

Impactful trials on dyslipidaemias, fractional flow reserve, beta-blockers, and peripheral artery disease.

European heart journal·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Heart failure is characterized by progressive left ventricular dilation.
  • Beta-blocker therapy is increasingly recognized for its potential benefits in heart failure management.
  • The exact mechanisms by which beta-blockers improve heart remodeling are still under investigation.

Purpose of the Study:

  • To explore the role of beta-blocker therapy in reversing or slowing left ventricular dilation in heart failure.
  • To investigate the underlying mechanisms of beta-blocker action on cardiac remodeling.
  • To assess the potential for personalized therapeutic approaches based on individual patient mechanisms.

Main Methods:

  • Review of current evidence on beta-blocker therapy in heart failure.

Related Experiment Videos

  • Analysis of studies investigating the effects of beta-blockers on left ventricular remodeling.
  • Exploration of potential cellular and molecular mechanisms involved in the beneficial effects.

    • Main Results:

    • Growing evidence suggests beta-blockers can reverse or slow left ventricular dilation.
    • A significant portion of long-term benefits appears mediated by beta-blocking action.
    • Direct effects on myocyte and interstitial growth may inhibit the remodeling process.

    Conclusions:

    • Beta-blocker therapy is a valuable tool in managing heart failure with left ventricular dilation.
    • Understanding the specific mechanisms of action is crucial for optimizing treatment strategies.
    • Future research may lead to more selective and personalized beta-blocker approaches for heart failure patients.